Simulation of Oral Glucose Tolerance Tests and the Corresponding Isoglycemic Intravenous Glucose Infusion Studies for Calculation of the Incretin Effect

The incretin effect, which is a unique stimulus of insulin secretion in response to oral ingestion of nutrients, is calculated by the difference in insulin secretory responses from an oral glucose tolerance test (OGTT) and a corresponding isoglycemic intravenous glucose infusion (IIGI) study. The OGTT model of this study, which is individualized by fitting the glucose profiles during an OGTT, was developed to predict the glucose profile during an IIGI study in the same subject. Also, the model predicts the insulin and incretin profiles during both studies. The incretin effect, estimated by simulation, was compared with that measured by physiologic studies from eight human subjects with normal glucose tolerance, and the result exhibited a good correlation (r > 0.8); the incretin effect from the simulation was 56.5% ± 10.6% while the one from the measured data was 52.5% ± 19.6%. In conclusion, the parameters of the OGTT model have been successfully estimated to predict the profiles of both OGTTs and IIGI studies. Therefore, with glucose data from the OGTT alone, this model could control and predict the physiologic responses, including insulin secretion during OGTTs and IIGI studies, which could eventually eliminate the need for complex and cumbersome IIGI studies in incretin research. Graphical Abstract

[1]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[2]  Sten Madsbad,et al.  Reduced Incretin Effect in Type 2 Diabetes , 2007, Diabetes.

[3]  Jens J. Holst,et al.  Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes , 2004, Regulatory Peptides.

[4]  M. Nauck,et al.  Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.

[5]  J. Holst,et al.  Reduced Incretin Effect in Type 2 Diabetes - Cause or Consequence of the Diabetic State? Received for publication 23 January 2007 and accepted in revised form 3 May 2007. , 2007 .

[6]  F. Toledo,et al.  Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[7]  Claudio Cobelli,et al.  Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. , 2004, American journal of physiology. Endocrinology and metabolism.

[8]  Micaela Morettini,et al.  Mathematical model of standard oral glucose tolerance test for characterization of insulin potentiation in health , 2012 .

[9]  Andrea Mari,et al.  Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. , 2006, American journal of physiology. Endocrinology and metabolism.

[10]  K. Park,et al.  Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus , 2011, Diabetes & metabolism journal.

[11]  C. Mcintosh,et al.  Pleiotropic actions of the incretin hormones. , 2010, Vitamins and hormones.

[12]  Henrik Madsen,et al.  Mathematical Beta Cell Model for Insulin Secretion following IVGTT and OGTT , 2006, Annals of Biomedical Engineering.

[13]  Alessandro Bertuzzi,et al.  Intestinal transit of a glucose bolus and incretin kinetics: a mathematical model with application to the oral glucose tolerance test. , 2011, American journal of physiology. Endocrinology and metabolism.

[14]  Andrea Tura,et al.  Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males. , 2011, The Journal of clinical endocrinology and metabolism.

[15]  Mark Ellrichmann,et al.  Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance , 2008, Diabetes.

[16]  Richard N Bergman,et al.  Orchestration of Glucose Homeostasis , 2007, Diabetes.

[17]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[18]  M. Durisová,et al.  Estimation of influence of gastric emptying on shape of glucose concentration-time profile measured in oral glucose tolerance test. , 2007, Diabetes research and clinical practice.

[19]  Karl Thomaseth,et al.  Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test , 2008, Comput. Methods Programs Biomed..

[20]  J. Holst,et al.  Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[21]  B. Göke,et al.  Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.

[22]  R. Hovorka,et al.  A simulation model of glucose regulation in the critically ill , 2008, Physiological measurement.

[23]  Biomedical Engineering Systems and Technologies - Third International Joint Conference, BIOSTEC 2010, Valencia, Spain, January 20-23, 2010, Revised Selected Papers , 2011, BIOSTEC.

[24]  Elan L. Ohayon,et al.  A Mathematical Model of the Oral Glucose Tolerance Test Illustrating the Effects of the Incretins , 2007, Annals of Biomedical Engineering.

[25]  M. Morari,et al.  Closed-Loop Control of Blood Glucose , 2007 .

[26]  J. Holst,et al.  Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects , 2003, Regulatory Peptides.